Coherus Shakes Up Ranibizumab Competition With First Interchangeable US Biosimilar
Cimerli Version Approved By FDA For All Five Indications Of Lucentis Reference Product
Coherus BioSciences has heralded a “strategic inflection point” for the company after receiving USFDA approval for Cimerli as an interchangeable biosimilar rival to Lucentis. The firm has also revealed launch plans for the Bioeq-partnered ranibizumab product.
